Skip to main content
SpringerLink
Log in

90Y-radioembolization of hepatocellular carcinoma from a theranostic perspective: towards a personalized approach

  • Letter to the Editor
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Ho CL, Chen S, Cheung SK, et al. Radioembolization with 90Y glass microspheres for hepatocellular carcinoma: significance of pretreatment 11C-acetate and 18F-FDG PET/CT and posttreatment 90Y PET/CT in individualized dose prescription. Eur J Nucl Med Mol Imaging. 2018. https://doi.org/10.1007/s00259-018-4064-6.

    Article  PubMed  Google Scholar 

  2. Salem R, Lewandowski RJ, Kulik L, Wang E, Riaz A, Ryu RK, et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology. 2011;140(2):497–507.

    Article  PubMed  Google Scholar 

  3. Ahmadzadehfar H, Essler M. It is time to move forward into the era of Theranostics. EJNMMI Res. 2018;8(1):9 https://doi.org/10.1186/s13550-018-0364-x.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Haug AR. Imaging of primary liver tumors with positron-emission tomography. Q J Nucl Med Mol Imaging. 2017;61(3):292–300 https://doi.org/10.23736/S1824-4785.17.02994-6.

    Article  PubMed  Google Scholar 

  5. Ma W, Jia J, Wang S, Bai W, Yi J, Bai M, et al. The prognostic value of 18F-FDG PET/CT for hepatocellular carcinoma treated with transarterial chemoembolization (TACE). Theranostics. 2014;4(7):736–44.

    Article  PubMed Central  PubMed  Google Scholar 

  6. Filippi L, Di Costanzo GG, D'Agostini A, Tortora R, Pelle G, Cianni R, et al. Decrease in total lesion glycolysis and survival after yttrium-90-radioembolization in poorly differentiated hepatocellular carcinoma with portal vein tumour thrombosis. Nucl Med Commun. 2018. https://doi.org/10.1097/MNM.0000000000000879.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nuclear Medicine Unit, “Santa Maria Goretti” Hospital, via Canova, Latina, Italy

    Luca Filippi & Oreste Bagni

  2. Department of Biomedicine and Prevention, University Tor Vergata, Rome, Italy

    Orazio Schillaci

  3. IRCCS Neuromed, Pozzilli, Italy

    Orazio Schillaci

Authors
  1. Luca Filippi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Orazio Schillaci
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Oreste Bagni
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Luca Filippi.

Ethics declarations

Conflict of interest

Luca Filippi, Orazio Schillaci, and Oreste Bagni declare that they have no conflicts of interest.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Informed consent

Not applicable, this is a Letter to the Editor.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Filippi, L., Schillaci, O. & Bagni, O. 90Y-radioembolization of hepatocellular carcinoma from a theranostic perspective: towards a personalized approach. Eur J Nucl Med Mol Imaging 45, 2238–2239 (2018). https://doi.org/10.1007/s00259-018-4115-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-018-4115-z

Search

Navigation